@daviddemesquita's peptide therapy claims fact-checked

What does this video actually claim?

David DeMesquita's TikTok promotes growth hormone testing and peptide therapy, specifically targeting bodybuilding and optimization audiences. The video appears to be a response about growth hormone levels and peptide interventions, though the specific medical claims are limited in the brief format.

The hashtags focus on growth hormone testing and peptide therapy. DeMesquita positions himself as an authority on peptide protocols, which is concerning given the lack of regulatory oversight in this space.

Does the science back up peptide therapy claims?

The peptide therapy market operates largely in a regulatory gray area, with most compounds lacking FDA approval for the uses promoted online. Growth hormone-releasing peptides like CJC-1295 and ipamorelin have shown some effects in small studies, but the evidence base is thin.

A 2019 study by Sigalos et al. in Sexual Medicine Reviews found that while some peptides can increase growth hormone levels, the clinical benefits remain unclear. The Tesamorelin trials (Falutz et al., NEJM, 2010) showed modest effects on visceral fat in HIV patients, but this doesn't translate to healthy adults seeking optimization.

Most peptide therapy claims rely on mechanism-based reasoning rather than clinical outcomes data. That's a red flag.

What regulatory issues should concern you?

The FDA has repeatedly warned compounding pharmacies about peptide products. In 2022, they issued warning letters to multiple companies selling research peptides for human use. Many peptides marketed for therapy aren't approved drugs.

BPC-157, one of the most hyped peptides, has zero human clinical trials despite widespread online promotion. TB-500 research exists only in animal models. Yet influencers regularly promote these as proven therapies.

The regulatory status matters because it affects quality control, dosing accuracy, and safety monitoring. You're essentially participating in an uncontrolled experiment.

What about growth hormone testing claims?

GH testing can be useful, but interpreting results requires understanding the hormone's pulsatile nature. Growth hormone fluctuates dramatically throughout the day, making single measurements often meaningless.

The gold standard insulin tolerance test is rarely done outside research settings due to safety concerns. IGF-1 levels provide a better marker of GH status, but normal aging causes predictable declines that don't necessarily require intervention.

DeMesquita's promotion of testing without discussing these limitations oversimplifies a complex endocrine assessment. Many people will get tests that don't actually inform treatment decisions.

What should you actually know about peptides?

Some peptides do have legitimate medical applications. Semaglutide and tirzepatide, both peptides, have strong clinical data for diabetes and weight management. But these went through proper FDA approval processes.

The optimization peptides promoted online lack this evidence base. They might have effects, but we don't know the long-term safety profile or optimal dosing. The research peptide market exploits regulatory loopholes.

If you're interested in peptide therapy, work with physicians who can prescribe FDA-approved options and monitor for side effects. Avoid the wild west of research peptides promoted by influencers.